“In the case of iLet, we're going to say, this is how much insulin they're getting for what they consider to be a usual meal. And we learn that and we can set it that way. So we just take the responsibility of learning carb counting, which is really tough, off the user's plate. That's an extra level of automation that traditional pumps don't provide,” Beta Bionics CEO Sean Saint explains to Bloomberg Intelligence. In this episode of Vanguards of Health Care, Saint sits down with BI analyst Matt Henriksson for an in-depth interview about Beta’s iLet pump, designed to eliminate the human stress of making insulin dosing decisions. The conversation also touches on the company’s pay as you go strategy through the pharmacy channel and future product development, including the Mint patch pump.

See omnystudio.com/listener for privacy information.

“If you’re not going overseas, you’re going out,” says Dr. Xingli Wang, Co-President of Fosun Pharma. He tells Bloomberg Intelligence’s Sam Fazeli how Fosun is transitioning from generics to novel medicines and positioning itself as a global innovator. With 90% of R&D now focused on oncology, autoimmune and neurodegenerative diseases, Wang details Fosun’s ambition to move from a China-based manufacturer to a multinational developer with true blockbuster potential. He also reflects on how disciplined capital investment, scientific partnerships and cultural persistence could make Fosun the “Takeda of China.”
Listen to this episode of Vanguards of Health Care on Apple Podcasts and Spotify

See omnystudio.com/listener for privacy information.

“What you have to do in a market like that, where it’s highly genericized, is first you have to have a clinical differentiation,” says Richard Lowenthal, CEO of ARS Pharmaceuticals. “You have to have a benefit to the community, benefit to the patient population. Neffy achieves that very effectively by providing an option that’s very simple — it’s easy to carry, it’s very easy to use.” In this episode of Vanguards of Health Care, Richard sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the company has navigated the commercial launch of its needle-free epinephrine nasal spray, neffy, in a highly competitive genericized market.

See omnystudio.com/listener for privacy information.